Supplementary Figure 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 7. Pharmacodynamic effect of givastomig on peripheral T cell subsets. Heatmap of absolute abundance (%) (panel A) and change from baseline in abundance (panel B) of 55 immune cell subsets among 238 blood samples collected from 33 patients treated with 0.1 – 15 mg/kg Q2W of givastomig. In total, 238 blood samples (in columns) collected from 33 patients at multiple time points were organized by patient IDs and visit time points, and patients were further grouped by dosing cohort, cancer type (GC vs. non-GC), CLDN18.2 status at baseline, and best overall response (BOR). 55 immune cell subsets (in rows) were hierarchically clustered.
Authors: Geoffrey Ku, Lin Shen, Farshid Dayyani, Jeremy Kratz, Xinjun Liang, Funan Liu, Zhenning Wang, Laura Feller, Eugenia Girda, Hongming Pan, Sunnie Kim, Yanhong Deng, Ting Deng, Tianshu Liu, John Powderly, Kristen Spencer, Reva Schneider, Jordan Berlin, Claire (Cong) Xu, Christoph M. Ahlers, Xuejun Liu, Jou-Ku Chung, Peter Sabbatini, Jinyoung Park, Yangmi Lim, Juyeun Jeon, Yuan Meng, Samuel J. Klempner
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416844611